miRNA-31和STAT-3在舌鳞状细胞癌中的表达及临床意义

摘要/Abstract

摘要： 目的:探讨miRNA-31和STAT-3在舌鳞状细胞癌中的变化及相关性。方法:收集137例舌鳞状细胞癌患者组织标本,利用荧光原位杂交法检测miRNA-31在组织中的表达情况,利用SP免疫组化法检测STAT-3在组织中表达情况,分析miRNA-31和STAT-3在不同分化程度舌鳞癌组织中表达,利用Kaplan-meier法分析miRNA-31和STAT-3表达与生存期的关系。结果:miRNA-31在低分化、中分化和高分化组织中阳性表达率分别为(80.6±14.3)%、(58.5±15.7)%和(23.7±9.4)%,STAT-3分别为(85.9±12.7)%、(51.7±16.3)%和(17.6±9.1)%,差异均具有统计学意义(P<0.05);Spearman等级相关分析显示,舌鳞癌组织中miRNA-31和STAT-3表达呈正相关(r=0.614,P<0.05);生存分析显示,miRNA-31高表达组患者中位生存期37个月,低表达组患者中位生存期65个月,STAT-3高表达组患者中位生存期38个月,低表达组患者中位生存期66个月,差异均具有统计学意义(P<0.001)。结论:miRNA-31和STAT-3舌鳞癌组织中表达与组织分化程度有关,且miRNA-31和STAT-3呈正相关,高表达可影响患者预后。

关键词: 舌鳞状细胞癌, miRNA-31, STAT-3, 表达, 相关性

Abstract: Objective: To investigate the expression levels of miRNA-31 and STAT-3 in patients with tongue squamous cell carcinoma (TSCC) and their clinical significances. Methods: 137 tissue samples of TSCC were collected. The expression of miRNA-31 was detected by fluorescence in situ hybridization, and the expression of STAT-3 was detected by immunohistochemistry. Meanwhile, the expression levels of miRNA-31 and STAT-3 in TSCC patients at different differentiation were evaluated. Correlations between miRNA-31 and STAT-3 expressions with survival time were also analyzed. Results: The percentages of miRNA-31 positive cells in poorly differentiated, moderately differentiated and highly differentiated were 80.6±14.3, 58.5±15.7 and 23.7±9.4, respectively. For STAT-3, the percentages of positive cells were 85.9±12.7, 51.7±16.3 and 17.6±9.1, respectively. The expression levels of miRNA-31 and STAT-3 at various degrees of cell differentiation were significantly different (P<0.05). MiRNA-31 was positively correlated with the expression of STAT-3 in TSCC (r=0.614, P<0.05). The median survival periods were 37 and 38 months in TSCC patients with high expression levels of miRNA-31 and STAT-3, while 65 and 66 months in low expression group (P<0.001). Conclusion: In TSCC, the expression levels of miRNA-31 and STAT-3 were positively correlated, which were also correlated with the degree of cell differentiation and prognosis of patient.

Key words: Tongue squamous cell carcinoma, MiRNA-31, STAT-3, Expression, Correlation

中图分类号:

R739.8

蔡洁明,舒传继,杨伟民,褚烛天. miRNA-31和STAT-3在舌鳞状细胞癌中的表达及临床意义[J]. 口腔医学研究, 2015, 31(8): 820-.

CAI Jie-ming, SHU Chuan-ji, YANG Wei-min, et al. Expressions of MiRNA-31 and STAT-3 in Tongue Squamous Cell Carcinoma and Their Clinical Significance[J]. Journal of Oral Science Research, 2015, 31(8): 820-.

参考文献

[1] Nyi Nyi MP, Gibson TN, Hanchard B, et al. Trends in incidence and age distribution of oral cavity and oropharyngeal squamous cell carcinomas, kingston and st andrew, Jamaica, 1978-2007[J]. West Indian Med J, 2014, 63(2)∶128-133
[2] 李莎莎,周旋,张强,等.STAT3 与miRNA-21 在舌鳞状细胞癌中异常表达的相关性研究[J].中国肿瘤临床,2013,40(6)∶323-327
[3] Mori M, Triboulet R, Mohseni M, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer [J]. Cell, 2014, 156(5)∶893-906
[4] Fu LL, Wen X, Bao JK, et al. MicroRNA-modulated autophagic signaling networks in cancer [J]. Int J Biochem Cell Biol, 2012, 44(5)∶733-736
[5] Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma [J]. Cancer Res, 2010, 70(4)∶1635-1644
[6] 黄媛媛,周旋,刘爱芹,等.信号传导与转录活化因子3抑制剂WP1066影响人舌鳞状细胞癌增殖与凋亡的研究[J].中华口腔医学杂志,2014,49(5)∶308-313
[7] 张学彦,吕成倩,杜冰,等.FAK在食管癌组织中的表达及临床意义[J].胃肠学和肝病学杂志,2014,23(8)∶866-869
[8] 刘杰,王晓雷,刘琳,等.前哨淋巴结活检在无临床淋巴结转移的早期舌癌临床治疗中的应用价值[J].中华肿瘤杂志,2013,35(6)∶459-462
[9] Wu DW, Chuang CY, Lin WL, et al. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting [J]. Carcinogenesis, 2014, 35(8)∶1823-1829
[10] 杨梅琳, 康玉, 洪珊珊, 等. 不同腹膜后淋巴结转移能力的卵巢癌细胞小RNA(miRNA)表达差异[J].复旦学报(医学版),2014,41(4)∶476-482
[11] Liu CJ1, Lin SC, Yang CC, et al. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma [J]. Head Neck, 2012, 34(2)∶219-224
[12] Chen T, Yao LQ, Shi Q, et al. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1) [J]. Cancer Biol Ther, 2014, 15(5)∶516-523
[13] Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma [J]. Clin Sci (Lond), 2011, 121(10)∶437-447
[14] Park JS, Kwok SK, Lim MA, et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis [J]. Arthritis Rheumatol, 2014, 66(4)∶918-929
[15] Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment [J]. Curr Med Chem, 2011, 18(16)∶2359-2375
[16] Bonner JA, Yang ES, Trummell HQ, et al. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma [J]. Radiother Oncol, 2011, 99(3)∶339-343